Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00106691 · ClinicalTrials.gov registry record · Phase 3
Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia)
A Phase 3 study, sponsored by GTx.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,589
- Enrollment target
NCT00106691: Completed Phase 3 study, sponsored by GTx.
NCT00106691 is a Phase 3 study that has completed, run by GTx. The registered enrollment target is 1,589 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (106% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00106691, a Phase 3 study, has completed, sponsored by GTx.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,589 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if toremifene citrate is effective and safe in the prevention of prostate cancer in men who have been diagnosed with high grade prostatic intraepithelial neoplasia (PIN).
Primary Outcome
To measure the efficacy of toremifene citrate in men with high grade prostatic intraepithelial neoplasia (PIN). Prostate cancer-free survival distributions (Kaplan-Meier)
Interventions
- DRUG Placebo
- DRUG Toremifene 20 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,589 participants |
| Start Date | 2005-01 |
| Est. Completion | 2010-02 |
| Phase | Phase 3 |
What the finished NCT00106691 record still lists
NCT00106691 is an interventional study that assigns participants to a tested intervention. Its 1,589 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (106% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00106691 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00106691 about?
NCT00106691 is a clinical study titled "Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia)". The purpose of this study is to determine if toremifene citrate is effective and safe in the prevention of prostate cancer in men who have been diagnosed with high grade prostatic intraepithelial neoplasia (PIN).
What is the current status of trial NCT00106691?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,589 participants. The study started on 2005-01. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00106691?
The interventions under investigation include: Placebo (DRUG), Toremifene 20 mg (DRUG).
Who is sponsoring clinical trial NCT00106691?
This trial is sponsored by GTx, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00106691's enrollment target sits among peer trials
1,589 149th of 2000 higher than 1,852 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05552222 · 1,590 participants · Phase 3
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- NCT06632457 · 1,590 participants · Phase 3
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
- NCT05243797 · 1,594 participants · Phase 3
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- NCT05483855 · 1,580 participants
Telehealth-delivered HealthcaRe to ImproVe Care
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia